Huixun Jia

Huixun Jia


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
WZWeiwei Zhao
Weiwei Zhao
PWPeng Wang
Peng Wang
HJHuixun Jia
Huixun Jia
MCMenglei Chen
Menglei Chen
XGXiaoli Gu
Xiaoli Gu
ZWZhenyu Wu
Zhenyu Wu
The lymphocytes played an important role in the natural history of cancer. The aim of this study was to explore the prognostic value of lymphocyte count and percentage for survival in advanced cancer patients receiving palliative care. A retrospective review of clinicopathological data from 378 consecutive advanced cancer patients and 106 extended follow-up patients treated with palliative care was conducted. Kaplan–Meier curves and multivariate cox regression analyses were used to evaluate the relationships of peripheral lymphocyte count (LC) and lymphocyte to white blood cell ratio (LWR) with overall survival (OS). The median values for pretreatment LC and LWR were 1.1 (IQR, 0.8 ~ 1.5 × 109/L) and 0.138 (IQR, 0.086 ~ 0.208). The median survival times across LWR quartiles were 19, 47, 79, and 101 days (P < 0.001). Multivariate analysis indicated that patients in the highest quartiles of LC and LWR had an HR of 1.082 (95% CI 0.777 ~ 1.506, P = 0.642) and 0.466 (95% CI 0.328 ~ 0.661, P < 0.001), respectively, compared with patients in the lowest quartiles. Furthermore, only the dynamic changes of LWR were confirmed as an independent prognostic factor for overall survival during the follow-up (HR = 0.396, 95% CI 0.243 ~ 0.668; P = 0.001), as were primary tumor site and ECOG. No effect was observed for the dynamic changes of LC. Our findings demonstrate that measurement of the dynamic changes of LWR prior to treatment and during follow-up may represent a simple and new powerful prognostic factor for patients with advanced cancer, unlike measurement of LC. As a bedside marker of immune status, the prognostic role of LWR should be further evaluated in prospective studies.

1 June 2023 in Heliyon
Verified
Journal Article
Open access
MZMin Zhang
Min Zhang
JWJinye Wu
Jinye Wu
YWYimin Wang
Yimin Wang
JWJiali Wu
Jiali Wu
WHWeiting Hu
Weiting Hu
Xiaodong SunXiaodong Sun
Xiaodong Sun
To evaluate the associations of blood pressure levels with diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) in patients with diabetes mellitus. A cross-sectional, population-based study. A total of 152,844 patients with diabetes from 90 major cities in 19 provincial regions of mainland China during 2018–2021 were finally recruited. Blood pressure was graded into 5 levels: normal (without hypertension and <120/80 mmHg), normal high (without hypertension and ≥120/80 mmHg), HT-intensive (hypertension and <120/80 mmHg), HT-moderate (hypertension and blood pressure between 120/80 mmHg and 140/90 mmHg) and HT-high (hypertension and ≥140/90 mmHg). Logistic regression was employed to verify the associations of hypertension and blood pressure levels with DR, PDR and DME. The impacts of blood pressure levels on the outcomes were qualified with nomogram models. The main outcome was DR. There were 16,685 (10.92%) participants having DR, 2841 (1.86%) having PDR, and 1566 (1.02%) having DME. There were 8126 (5.32%) patients without hypertension and 1350 (0.88%) patients with hypertension having blood pressure 120/80 mmHg in both patients with and without hypertension. A nomogram was developed for DR prediction based on blood pressure levels.

5 March 2024 in Eco-Environment & Health
Verified
Journal Article
Open access
YWYu Wen
Yu Wen
YWYibaina Wang
Yibaina Wang
Renjie ChenRenjie Chen
Renjie Chen
YGYi Guo
Yi Guo
JPJialu Pu
Jialu Pu
ZWZhenyu Wu
Zhenyu Wu
The association between the exposure of organochlorine pesticides (OCPs) and serum uric acid (UA) levels remained uncertain. In this study, to investigate the combined effects of OCP mixtures on hyperuricemia, we analyzed serum OCPs and UA levels in adults from the National Health and Nutrition Examination Survey (2005–2016). Four statistical models including weighted logistic regression, weighted quantile sum (WQS), quantile g-computation (QGC), and bayesian kernel machine regression (BKMR) were used to assess the relationship between mixed chemical exposures and hyperuricemia. Subgroup analyses were conducted to explore potential modifiers. Among 6,529 participants, the prevalence of hyperuricemia was 21.15%. Logistic regression revealed a significant association between both hexachlorobenzene (HCB) and trans-nonachlor and hyperuricemia in the fifth quintile (OR: 1.54, 95% CI: 1.08–2.19; OR: 1.58, 95% CI: 1.05–2.39, respectively), utilizing the first quintile as a reference. WQS and QGC analyses showed significant overall effects of OCPs on hyperuricemia, with an OR of 1.25 (95% CI: 1.09–1.44) and 1.20 (95% CI: 1.06–1.37), respectively. BKMR indicated a positive trend between mixed OCPs and hyperuricemia, with HCB having the largest weight in all three mixture analyses. Subgroup analyses revealed that females, individuals aged 50 years and above, and those with a low income were more vulnerable to mixed OCP exposure. These results highlight the urgent need to protect vulnerable populations from OCPs and to properly evaluate the health effects of multiple exposures on hyperuricemia using mutual validation approaches.

1 October 2021 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
TLTong Li
Tong Li
JSJunran Sun
Junran Sun
JMJingyu Min
Jingyu Min
SZShuangwen Zhou
Shuangwen Zhou
XZXiaolin Zhu
Xiaolin Zhu
XSXiaodong Sun
Xiaodong Sun
First described at the turn of the 20th century for repairing retinal detachments (RDs), intravitreal injections (IVIs) have become the most widely performed procedures in the ophthalmic field.1 IVIs with anti–vascular endothelial growth factor (VEGF) agents have significantly improved management and visual prognosis of angiogenic retinal diseases, including neovascular age-related macular degeneration, diabetic macular edema, retinal vein occlusion, proliferative diabetic retinopathy, choroidal neovascularization, and other visual impairments.2

25 July 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZWZhenyu Wu
Zhenyu Wu
GQGuoyou Qin
Guoyou Qin
NZNaiqing Zhao
Naiqing Zhao
HJHuixun Jia
Huixun Jia
XZXueying Zheng
Xueying Zheng
According to the current official guidelines, at least 12 lymph nodes (LNs) are qualified as an adequate sampling for colon cancer patients. However, patients evaluated with less nodes were still common in the United States, and the prevalence of positive nodal disease may be under-estimated because of the false-negative assessment. In this study, we present a statistical model that allows preoperative determination of the minimum number of lymph nodes needed to confirm a node-negative disease with certain confidence. Adenocarcinoma colon cancer patients with stage T1-T3, diagnosed between 2004 and 2013, who did not receive neoadjuvant therapies and had at least one lymph node pathologically examined, were extracted from the Surveillance, Epidemiology and End Results (SEER) database. A beta binomial distribution was used to estimate the probability of an occult nodal disease is truly node-negative as a function of total number of LNs examined and T stage. A total of 125,306 patients met study criteria; and 47,788 of those were node-positive. The probability of falsely identifying a patient as node-negative decreased with an increasing number of nodes examined for each stage, and was estimated to be 72% for T1 and T2 patients with a single node examined and 57% for T3 patients with a single node examined. To confirm an occult nodal disease with 90% confidence, 3, 8, and 24 nodes need to be examined for patients from stage T1, T2, and T3, respectively. The false-negative rate of diagnosed node negative, together with the minimum number of examined nodes for adequate staging, depend preoperatively on the clinical T stage. Predictive tools can recommend a threshold on the minimum number of examined nodes regarding to the favored level of confidence for each T stage.

5 June 2019 in BMC Palliative Care
Verified
Journal Article
Open access
PDF file
WZWeiwei Zhao
Weiwei Zhao
ZHZhiyong He
Zhiyong He
YLYintao Li
Yintao Li
HJHuixun Jia
Huixun Jia
MCMenglei Chen
Menglei Chen
WCWenwu Cheng
Wenwu Cheng
Although palliative care has been accepted throughout the cancer trajectory, accurate survival prediction for advanced cancer patients is still a challenge. The aim of this study is to identify pre-palliative care predictors and develop a prognostic nomogram for overall survival (OS) in mixed advanced cancer patients. A total of 378 consecutive advanced cancer patients were retrospectively recruited from July 2013 to October 2015 in one palliative care unit in China. Twenty-three clinical and laboratory characters were collected for analysis. Prognostic factors were identified to construct a nomogram in a training cohort (n = 247) and validated in a testing cohort (n = 131) from the setting. The median survival time was 48.0 (95% CI: 38.1–57.9) days for the training cohort and 52.0 (95% CI: 34.6–69.3) days for the validation cohort. Among pre-palliative care factors, sex, age, tumor stage, Karnofsky performance status, neutrophil count, hemoglobin, lactate dehydrogenase, albumin, uric acid, and cystatin-C were identified as independent prognostic factors for OS. Based on the 10 factors, an easily obtained nomogram predicting 90-day probability of mortality was developed. The predictive nomogram had good discrimination and calibration, with a high C-index of 0.76 (95% CI: 0.73–0.80) in the development set. The strong discriminative ability was externally conformed in the validation cohort with a C-index of 0.75. A validated prognostic nomogram has been developed to quantify the risk of mortality for advanced cancer patients undergoing palliative care. This tool may be useful in optimizing therapeutic approaches and preparing for clinical courses individually.